Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience.
Oligometastatic
Oligoprogressive
SBRT
Stereotactic body radiation therapy
Urothelial cancer
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
16 Jun 2024
16 Jun 2024
Historique:
received:
22
04
2024
accepted:
06
06
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
16
6
2024
Statut:
epublish
Résumé
Standard treatment options for patients with metastatic urothelial cancer (mUC) include systemic platinum-based chemotherapy, immunotherapy, antibody-drug-conjugates, and targeted therapy. Oligometastatic disease (OMD) may be an intermediate state between localized and generalized cancer. The best treatment strategy for OMD and oligoprogressive (OPD) disease is poorly studied in mUC but local stereotactic body radiation therapy (SBRT) could be an option to avoid or delay systemic treatment. The aim of this study was to assess the efficacy and feasibility of SBRT given in a real-world patient population. All patients with mUC treated with SBRT at Karolinska University Hospital, Stockholm, Sweden between 2009 and 2022 were included in this study. Baseline clinical characteristics, treatment data, SBRT dosimetry data and treatment outcome were collected retrospectively. The study endpoints were local control rate (LCR), progression-free-survival (PFS), overall survival (OS) and feasibility of SBRT. In total 39 patients were treated with SBRT. The median follow-up was 25.6 months. The LCR was 82%. PFS and OS were 4.1 and 26.2 months, respectively. Treatment was well tolerated; all patients but one (treatment related pain) completed the planned SBRT. Number of metastases irradiated with SBRT was significantly associated with outcome; patients with only one irradiated lesion had more favourable PFS compared to individuals with 2 or more metastases (HR 4.12, 95% CI: 1.81-9.38, p = 0.001). A subgroup of patients (15%) achieved a sustained long-term survival benefit and never required systemic treatments after SBRT. SBRT was well tolerated and associated with high LCR. A subpopulation of patients with single metastatic lesion achieved long-term OS and never required subsequent systemic treatment after SBRT. Prospective randomized studies are warranted to discover treatment predictive biomarkers and to investigate the role of SBRT in oligometastatic UC.
Sections du résumé
BACKGROUND
BACKGROUND
Standard treatment options for patients with metastatic urothelial cancer (mUC) include systemic platinum-based chemotherapy, immunotherapy, antibody-drug-conjugates, and targeted therapy. Oligometastatic disease (OMD) may be an intermediate state between localized and generalized cancer. The best treatment strategy for OMD and oligoprogressive (OPD) disease is poorly studied in mUC but local stereotactic body radiation therapy (SBRT) could be an option to avoid or delay systemic treatment. The aim of this study was to assess the efficacy and feasibility of SBRT given in a real-world patient population.
METHODS
METHODS
All patients with mUC treated with SBRT at Karolinska University Hospital, Stockholm, Sweden between 2009 and 2022 were included in this study. Baseline clinical characteristics, treatment data, SBRT dosimetry data and treatment outcome were collected retrospectively. The study endpoints were local control rate (LCR), progression-free-survival (PFS), overall survival (OS) and feasibility of SBRT.
RESULTS
RESULTS
In total 39 patients were treated with SBRT. The median follow-up was 25.6 months. The LCR was 82%. PFS and OS were 4.1 and 26.2 months, respectively. Treatment was well tolerated; all patients but one (treatment related pain) completed the planned SBRT. Number of metastases irradiated with SBRT was significantly associated with outcome; patients with only one irradiated lesion had more favourable PFS compared to individuals with 2 or more metastases (HR 4.12, 95% CI: 1.81-9.38, p = 0.001). A subgroup of patients (15%) achieved a sustained long-term survival benefit and never required systemic treatments after SBRT.
CONCLUSIONS
CONCLUSIONS
SBRT was well tolerated and associated with high LCR. A subpopulation of patients with single metastatic lesion achieved long-term OS and never required subsequent systemic treatment after SBRT. Prospective randomized studies are warranted to discover treatment predictive biomarkers and to investigate the role of SBRT in oligometastatic UC.
Identifiants
pubmed: 38880908
doi: 10.1186/s13014-024-02465-y
pii: 10.1186/s13014-024-02465-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Informations de copyright
© 2024. The Author(s).
Références
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer [Internet]. 2024 [cited 2024 Mar 05]. https://gco.iarc.who.int/today .
Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34. https://doi.org/10.1016/j.urology.2005.07.062 .
doi: 10.1016/j.urology.2005.07.062
pubmed: 16399414
Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788 .
doi: 10.1056/NEJMoa2002788
pubmed: 32945632
Powles T, Park SH, Caserta C, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: results from the JAVELIN bladder 100 Trial after ≥ 2 years of Follow-Up. J Clin Oncol. 2023;41(19):3486–92. https://doi.org/10.1200/JCO.22.01792 .
doi: 10.1200/JCO.22.01792
pubmed: 37071838
pmcid: 10306435
Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in previously treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125–35. https://doi.org/10.1056/NEJMoa2035807 .
doi: 10.1056/NEJMoa2035807
pubmed: 33577729
pmcid: 8450892
Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of Sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85. https://doi.org/10.1200/JCO.20.03489 .
doi: 10.1200/JCO.20.03489
pubmed: 33929895
pmcid: 8315301
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338–48. https://doi.org/10.1056/NEJMoa1817323 .
doi: 10.1056/NEJMoa1817323
pubmed: 31340094
Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8 .
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003 .
doi: 10.1016/j.radonc.2020.04.003
pubmed: 32388150
Patel V, Collazo Lorduy A, Stern A, et al. Survival after Metastasectomy for Metastatic Urothelial Carcinoma: a systematic review and Meta-analysis. Bladder Cancer. 2017;3(2):121–32. https://doi.org/10.3233/BLC-170108 . Published 2017 Apr 27.
doi: 10.3233/BLC-170108
pubmed: 28516157
pmcid: 5409038
Longo N, Celentano G, Napolitano L, et al. Metastasis-Directed Radiation Therapy with Consolidative Intent for Oligometastatic Urothelial Carcinoma: a systematic review and Meta-analysis. Cancers (Basel). 2022;14(10):2373. https://doi.org/10.3390/cancers14102373 . Published 2022 May 11.
doi: 10.3390/cancers14102373
pubmed: 35625979
pmcid: 9139743
Abe T, Minami K, Harabayashi T et al. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy [published correction appears in Jpn J Clin Oncol. 2020;50(6):727]. Jpn J Clin Oncol. 2020;50(2):206–213. https://doi.org/10.1093/jjco/hyz152 .
Aboudaram A, Chaltiel L, Pouessel D, et al. Consolidative radiotherapy for metastatic urothelial bladder Cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers (Basel). 2023;15(4):1161. https://doi.org/10.3390/cancers15041161 . Published 2023 Feb 11.
doi: 10.3390/cancers15041161
pubmed: 36831503
Augugliaro M, Marvaso G, Ciardo D, et al. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neoplasma. 2019;66(1):160–5. https://doi.org/10.4149/neo_2018_180522N333 .
doi: 10.4149/neo_2018_180522N333
pubmed: 30509099
Francolini G, Desideri I, Detti B, et al. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun. 2019;19:100124. https://doi.org/10.1016/j.ctarc.2019.100124 .
doi: 10.1016/j.ctarc.2019.100124
pubmed: 30851645
Franzese C, Francolini G, Nicosia L, Alongi F, Livi L, Scorsetti M. Stereotactic body Radiation Therapy in the management of Oligometastatic and oligoprogressive bladder Cancer and other Urothelial malignancies. Clin Oncol (R Coll Radiol). 2021;33(1):50–6. https://doi.org/10.1016/j.clon.2020.07.008 .
doi: 10.1016/j.clon.2020.07.008
pubmed: 32723486
Leonetti A, D’Abbiero N, Baldari G, et al. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol. 2018;25(10):879–86. https://doi.org/10.1111/iju.13773 .
doi: 10.1111/iju.13773
pubmed: 30103254
Wong RKS, Liu ZA, Barry A, et al. Patient-reported and clinical outcomes from 5-Fraction SBRT for oligometastases: a prospective single-Institution Study. Int J Radiat Oncol Biol Phys. 2022;114(5):1000–10. https://doi.org/10.1016/j.ijrobp.2022.07.025 .
doi: 10.1016/j.ijrobp.2022.07.025
pubmed: 35901981
Svedman C, Sandström P, Pisa P, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45(7):870–5. https://doi.org/10.1080/02841860600954875 .
doi: 10.1080/02841860600954875
pubmed: 16982552
Lindberg K, Nyman J, Riesenfeld Källskog V, et al. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the nordic experience. Acta Oncol. 2015;54(8):1096–104. https://doi.org/10.3109/0284186X.2015.1020966 .
doi: 10.3109/0284186X.2015.1020966
pubmed: 25813471
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683 .
doi: 10.1056/NEJMoa1613683
pubmed: 28212060
pmcid: 5635424
de la Fenor MD, Villacampa G, Miñana B, et al. First-line management of metastatic Urothelial Cancer: current and future perspectives after the EV-302 and CheckMate-901 studies. Clin Genitourin Cancer. Published Online Dec. 2023;13. https://doi.org/10.1016/j.clgc.2023.12.001 .
Sindhu KK, Leiter A, Moshier E, et al. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. Cancer Treat Res Commun. 2020;25:100216. https://doi.org/10.1016/j.ctarc.2020.100216 .
doi: 10.1016/j.ctarc.2020.100216
pubmed: 33049542
Daro-Faye M, Kassouf W, Souhami L, et al. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol. 2021;39(5):1331–43. https://doi.org/10.1007/s00345-020-03440-4 .
doi: 10.1007/s00345-020-03440-4
pubmed: 32915313